Autolus Therapeutics (AUTL) Goldman Sachs 46th Annual Global Healthcare Conference summary

Company overview and core focus areas

• Focuses on autologous CAR-T cell therapy, with lead program Obe-cel (AUCATZYL) approved in the U.S. in November and currently launching there.

• Differentiation of Obe-cel centers on unique design, offering improved safety and efficacy, as shown in the FELIX study.

• Built a proprietary manufacturing facility in the U.K., providing commercial capacity and competitive advantage.

• Pipeline includes additional CAR-T programs in collaboration with UCL, with early phase data expected.

• Plans to expand Obe-cel into new indications, including autoimmune diseases like lupus and MS.

Launch progress and commercial execution

• U.S. launch of AUCATZYL ahead of internal and consensus expectations, with strong center onboarding and payer access.

• Over 40 centers onboarded by mid-year, targeting 60 by year-end to reach 90% of addressable U.S. patients.

• Majority of centers have treated patients, though there is a lag between onboarding and treatment.

• Positive early feedback on safety profile, with reduced severe adverse events and hospital resource needs.

• Commercial infrastructure and real-time collaboration with centers cited as key to successful launch.

Financial performance and outlook

• Q1 revenue reached $9 million, with some deferred revenue; gross margin impacted by underutilized plant capacity.

• Gross margin expected to improve with higher plant utilization and sales ramp; long-term target is 15–20% of U.S. sales.

• European launch progressing, with conditional approval in the U.K. and CHMP positive opinion in the EU; initial focus on Germany.

• Expansion into pediatric ALL under regulatory commitment, with data expected in the second half of the year.